Avicanna Expands Global Reach with First CBG Flower Export to Australia
Event summary
- Avicanna's subsidiary SMGH completed its first commercial export of CBG-dominant cannabis flower to Australia on March 26, 2026.
- This marks the 21st market for SMGH and the 24th for all Avicanna products.
- SMGH's operations are aligned with international regulatory expectations for active pharmaceutical ingredients (API) and raw materials.
- SMGH's facility has 300,000 square feet of cultivation space and an extraction capacity of 300kg, with an annual yield of approximately 26,400 kg.
The big picture
Avicanna's successful export to Australia underscores its strategic focus on international expansion and regulatory compliance. The company's ability to produce consistent, standardized cannabis flower at commercial scale positions it well to capitalize on the growing global demand for medical cannabis products. This move also highlights the importance of structural strengths such as year-round cultivation and established genetic portfolios in supporting consistent production cycles and cost efficiencies.
What we're watching
- Market Expansion
- How Avicanna will leverage this export to penetrate other high-potential markets in the Asia-Pacific region.
- Regulatory Compliance
- Whether SMGH can maintain its GACP and organic certifications while scaling operations to meet increasing global demand.
- Operational Efficiency
- The pace at which SMGH can optimize its production cycles and batch uniformity to support long-term participation in international medical cannabis markets.